638674

research-article2016

DSTXXX10.1177/1932296816638674Journal of Diabetes Science and TechnologyLayne et al

Original Article

Efficacy of the Omnipod Insulin Management System on Glycemic Control in Patients With Type 1 Diabetes Previously Treated With Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion

Journal of Diabetes Science and Technology 2016, Vol. 10(5) 1130­–1135 © 2016 Diabetes Technology Society Reprints and permissions: sagepub.com/journalsPermissions.nav DOI: 10.1177/1932296816638674 dst.sagepub.com

Jennifer E. Layne, PhD1, Christopher G. Parkin, MS2, and Howard Zisser, MD1 Abstract Background: Continuous subcutaneous insulin infusion (CSII) treatment with a tubeless patch pump has not been previously evaluated in a large cohort of patients. Methods: This multisite, retrospective study evaluated glycemic control in patients with type 1 diabetes (n = 873) after 3 months treatment the Omnipod® insulin management system (Insulet Corporation, Billerica, MA) compared to prior treatment with multiple daily injections (MDI) (78.1%) or CSII (21.9%). The primary outcome was change in HbA1c from baseline at 3 months post–Omnipod treatment initiation. Secondary outcomes included shifts in HbA1c to target levels, change in total daily dose (TDD) of insulin and in the frequency and severity of hypoglycemic episodes. Results: HbA1c was significantly improved at 3 months post–Omnipod treatment for the total population (mean ± SD): –0.6% ± 1.3 (P < .001). HbA1c was also significantly lower compared to MDI: –0.3% ± 1.3, –0.4% ± 1.4, –0.8% ± 1.3 and –0.6% ± 1.3 (P = .002 to P < .001) and CSII: –0.3% ± 0.8, –1.1% ± 1.6 (P < .01), –0.4% ± 1.1 (P < .001), and –0.5% ± 1.1 (P < .001) for pediatric, adolescent, adult, and total populations, respectively. There was a 37.9% change increase in the proportion of patients ≥18 years and a 39.3% change increase in those